Targeted therapies against non-small-cell lung cancer (NSCLC) harboringPatients with stage IIIB or IVBetween October 20, 2016, and December 10, 2018, 60 patients received pyrotinib monotherapy. At baseline, 58 (96.7%) were stage IV, and 25 (41.7%) received at least 2 lines of prior chemotherapy. As of data cutoff on June 20, 2019, IRC-assessed objective response rate was 30.0% (95% CI, 18.8% to 43.2%). All subgroups of patients with differentPyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with